Summary of Key Points
This news report highlights new initiatives taken by Beijing to promote innovation in the pharmaceutical sector. By hosting the first Pharmaceutical Collaborative Innovation Conference and releasing the "Beijing Consensus," the city aims to establish a comprehensive framework that connects clinical needs with scientific research and industrial transformation. It also discusses the current state of pharmaceutical innovation in China: while there have been recent advancements, there is still a structural gap compared to the United States. The main challenges include hospitals' failure to fully leverage their role as sources of original innovation and the lack of "patient capital" to support high-risk, long-duration projects. Beijing plans to overcome these obstacles by leveraging its superior medical resources, establishing project databases to connect with investors, and strengthening clinical innovation efforts in order to advance the biopharmaceutical industry.
I. Pharmaceutical Innovation in China: Promising Progress but Significant Gaps
Positive Developments: In the first half of this year, the number of domestically developed innovative drugs targeting new targets or mechanisms reached a record high, including a globally novel radioactive drug developed by a hospital. Over the past three years, major hospitals such as Peking Union Medical College Hospital and West China Hospital have facilitated the entry of more than ten "first-in-class" (FIC) drugs into clinical trials.
Challenges: Among the 151 FIC drugs approved globally between 2016 and 2025, only eight were from China. The issue lies in the fact that new drug development often begins with unmet clinical needs. The discovery of new therapeutic targets relies on hospital data and research, yet many Chinese hospitals function primarily as testing sites rather than centers of innovation. Additionally, these high-risk, long-term projects (often lasting more than ten years) face a shortage of "patient capital" and lack effective mechanisms to attract sustained funding.
II. The Four Key Measures of the "Beijing Consensus"
The consensus focuses on driving innovation across the entire value chain and proposes the following actions:
1. Transform Hospitals into Sources of Innovation: Support Beijing's hospitals in establishing incubation platforms to cultivate stable research teams that can transform clinical challenges (such as the lack of effective treatments for certain diseases) into tangible research projects, involving collaboration among doctors, researchers, and enterprises.
2. Create a Smooth Path from Laboratory to Market: Establish innovation partnerships led by governments, major hospitals, and leading companies to involve businesses earlier in the development process (e.g., in product positioning and regulatory planning), ensuring that projects are both practical and profitable.
3. Unleash the Power of Data: Address the difficulty in sharing clinical and research data by turning it into valuable resources for drug and medical device innovation, with initial efforts focused on creating demonstration scenarios.
4. Support Early-Stage Innovation with Capital: Develop a pharmaceutical innovation transformation project database to match high-quality projects with patient capital, and encourage investment institutions to get involved earlier (e.g., through milestone-based investments) to provide continuous funding at various stages of development.
III. Why Beijing is in a Position to Take the Lead
Beijing boasts unique resources, including 81 top-tier hospitals, 13 national medical centers, and 23 national clinical research institutes, handling over 300 million medical consultations annually, which generates extensive clinical data. The city is also home to prestigious institutions such as Peking University Health Science Center and Tsinghua University School of Medicine. These resources position Beijing as a hub for pharmaceutical innovation. The consensus emphasizes that the key to advancing the biopharmaceutical industry lies in leveraging clinical needs, transforming research into market-ready products, and fostering collaboration among all stakeholders.
IV. Three Priorities for Further Reform
The Deputy Secretary-General of the Beijing Municipal Government has outlined the following directions for deeper reforms:
1. Cultivate Clinicians as Scientists: Train doctors to combine medical expertise with research capabilities, ensuring that clinical needs guide the direction of drug development.
2. Overcome Barriers in the Final Stage of Innovation: Eliminate obstacles in the coordination among healthcare, insurance, and pharmaceutical sectors to facilitate the adoption of innovative drugs and devices in hospitals.
3. Standardize Data Sharing and Sample Banks: Accelerate the sharing of clinical data and establish standardized biological sample banks to support original research.
V. The Significance of This Conference
Zhang Shuyang, President of the China Pharmaceutical Promotion Association, highlighted three significant breakthroughs achieved by this conference:
- For the first time, top medical schools (Peking University, Tsinghua University, Capital Medical University) and industry organizations collaborated to establish a transformation platform.
- For the first time, more than 100 cutting-edge projects stemming from clinical challenges were systematically gathered.
- For the first time, a mechanism was established to connect clinical experts with industry investors at an early stage.
These efforts reflect the philosophy of "clinical-driven innovation," which aims to use doctors' clinical experience and needs as the starting point for new drug development.
In summary, Beijing's initiatives aim to address the challenges in bringing pharmaceutical innovation from its initial stages to market readiness. By transforming hospitals into centers of innovation and attracting capital to support early-stage projects, the city hopes to promote more original Chinese drugs to the global market.